Kainos Medicine, Inc. (KOSDAQ:284620)
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Revenue
Kainos Medicine had revenue of 408.03M KRW in the quarter ending June 30, 2026, with 131.20% growth. This brings the company's revenue in the last twelve months to 1.40B, up 71.24% year-over-year. In the year 2025, Kainos Medicine had annual revenue of 1.17B with 98.46% growth.
Revenue (ttm)
1.40B
Revenue Growth
+71.24%
P/S Ratio
25.31
Revenue / Employee
n/a
Employees
n/a
Market Cap
35.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | 581.27M | 98.46% |
| Dec 31, 2024 | 590.37M | 323.05M | 120.85% |
| Dec 31, 2023 | 267.31M | 137.29M | 105.59% |
| Dec 31, 2022 | 130.02M | -1.53B | -92.18% |
| Dec 31, 2021 | 1.66B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| Eutilex.Co.,Ltd | 7.71B |
| QuadMedicine | 7.14B |
| HLB Pep | 5.54B |
| Parataxis Korea | 1.59B |
| NovMetaPharma | 1.30B |
| Quratis | 1.10B |
| CHOOLIP & SCIENCES | 1.08B |